anti-Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Antikörper

The protein encoded by ST14 is an epithelial-derived, integral membrane serine protease. Zusätzlich bieten wir Ihnen Suppression of Tumorigenicity 14 (Colon Carcinoma) Kits (7) und Suppression of Tumorigenicity 14 (Colon Carcinoma) Proteine (7) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
ST14 6768 Q9Y5Y6
ST14 19143 P56677
ST14 114093  
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top anti-Suppression of Tumorigenicity 14 (Colon Carcinoma) Antikörper auf antikoerper-online.de

Showing 10 out of 108 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Lieferzeit Preis Details
Rind (Kuh) Kaninchen Unkonjugiert WB WB Suggested Anti-ST14 Antibody Titration:  0.2-1 ug/ml  Positive Control:  THP-1 cell lysate WB Suggested Anti-ST14  Antibody Titration: 0.2-1 µg/mL  Positive Control: THP-1 cell lysate 100 μL 2 bis 3 Tage
$289.00
Details
Rind (Kuh) Kaninchen Unkonjugiert IHC, WB WB Suggested Anti-ST14 Antibody Titration:  0.25ug/ml  Positive Control:  DLD1 cell lysate ST14 is strongly supported by BioGPS gene expression data to be expressed in Human DLD1 cells 100 μL 2 bis 3 Tage
$319.00
Details
Human Kaninchen Unkonjugiert WB Western blot analysis of Matriptase expression in HeLa (A), SW620 (B) whole cell lysates. 200 μL 13 bis 14 Tage
$487.50
Details
Human Kaninchen Unkonjugiert WB 100 μg 2 bis 3 Tage
$245.00
Details
Human Kaninchen Unkonjugiert IF, ELISA, WB Western blot analysis of extracts from A549 cells, using ST14 Antibody. The lane on the right is treated with the synthesized peptide. Immunofluorescence analysis of A549 cells, using ST14 Antibody. The picture on the right is treated with the synthesized peptide. 100 μg 2 bis 3 Tage
$302.50
Details
Human Kaninchen Unkonjugiert IF (p), IHC (p), WB Formalin-fixed and paraffin embedded human endometrium carcinoma labeled with Rabbit Anti-Matriptase Polyclonal Antibody (ABIN669726), Unconjugated at 1:100 followed by conjugation to the secondary antibody and DAB staining. Formalin-fixed and paraffin embedded human endometrium carcinoma labeled with Rabbit Anti-Matriptase Polyclonal Antibody (ABIN669726), Unconjugated at 1:100 followed by conjugation to the secondary antibody and DAB staining. 100 μL 3 bis 7 Tage
$317.90
Details
Human Kaninchen Unkonjugiert EIA, IF, IHC (p), WB Immunofluorescence analysis of A549 cells, using ST14 Antibody. The picture on the right is treated with the synthesized peptide. Human Prostate: Formalin-Fixed, Paraffin-Embedded (FFPE) 50 μL 11 bis 13 Tage
$768.40
Details
Human Kaninchen Unkonjugiert ELISA, IF, WB 100 μL Verfügbar
$363.46
Details
Human Kaninchen Unkonjugiert ELISA, IF, IHC, IHC (p), WB Human Prostate: Formalin-Fixed, Paraffin-Embedded (FFPE) Human Small Intestine: Formalin-Fixed, Paraffin-Embedded (FFPE) 50 μL 11 bis 14 Tage
$484.00
Details
Human Kaninchen Unkonjugiert ELISA, IHC, IHC (p) Human Kidney (formalin-fixed, paraffin-embedded) stained with ST14 antibody ABIN214709 at 10 ug/ml followed by biotinylated goat anti-rabbit IgG secondary antibody ABIN481713, alkaline phosphatase-streptavidin and chromogen. Anti-ST14 / Matriptase antibody IHC of human kidney. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/ml. 50 μg 11 bis 14 Tage
$484.00
Details

Am meisten referenzierte anti-Suppression of Tumorigenicity 14 (Colon Carcinoma) Antikörper

  1. Human Polyclonal ST14 Primary Antibody für CyTOF, FACS - ABIN4900442 : Sales, Masedunskas, Bey, Rasmussen, Weigert, List, Szabo, Overbeek, Bugge: Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. in Nature genetics 2010 (PubMed)
    Show all 13 Pubmed References

  2. Human Polyclonal ST14 Primary Antibody für IP, WB - ABIN250689 : Désilets, Longpré, Beaulieu, Leduc: Inhibition of human matriptase by eglin c variants. in FEBS letters 2006 (PubMed)
    Show all 6 Pubmed References

  3. Human Polyclonal ST14 Primary Antibody für ELISA - ABIN545752 : Ihara, Miyoshi, Ko, Murata, Nakahara, Honke, Dickson, Lin, Taniguchi: Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. in The Journal of biological chemistry 2002 (PubMed)
    Show all 3 Pubmed References

  4. Human Monoclonal ST14 Primary Antibody für CyTOF, FACS - ABIN4900443 : Zoratti, Tanabe, Varela, Murray, Bergum, Colombo, Lang, Molinolo, Leduc, Marsault, Boerner, List: Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling. in Nature communications 2015 (PubMed)
    Show all 3 Pubmed References

  5. Human Monoclonal ST14 Primary Antibody für ELISA - ABIN520529 : Sasaroli, Gimotty, Pathak, Hammond, Kougioumtzidou, Katsaros, Buckanovich, Devarajan, Sandaltzopoulos, Godwin, Scholler, Coukos: Novel surface targets and serum biomarkers from the ovarian cancer vasculature. in Cancer biology & therapy 2011 (PubMed)

Weitere Antikörper gegen Suppression of Tumorigenicity 14 (Colon Carcinoma) Interaktionspartner

Human Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Interaktionspartner

  1. CDX2 has a dual function in regulating both ST14 and SPINT1, gene expression in intestinal cells. We find that CDX2 is not required for the basal ST14 and SPINT1 gene expression; however changes in CDX2 expression affects the ST14/SPINT1 mRNA ratio.

  2. Results indicate that Kunitz Domain I (KD1) of hepatocyte growth factor activator inhibitor-2 (HAI-2) plays a major role in the inhibition of cellular matritptase activation as well as prostate cancer motility.

  3. Our findings suggest that the high stromal matriptase expression was strongly associated with tumor progression, recurrence and poor outcomes in patients with extrahepatic bile duct cancer.

  4. used a bioinformatics approach to assess the impact of amino acid (AA) substitutions on the sensitivity of cytoskeletal and ECM peptides to the ST14 protease; Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme.

  5. the data strongly advocate this ST14 variant as the underlying genetic cause of autosomal recessive ichthyosis with hypotrichosis syndrome in this first reported affected family from Pakistan. Moreover, the present study adds to the spectrum of mutations in the ST14 gene, implicating them in the pathogenesis of autosomal recessive ichthyosis with hypotrichosis syndrome.

  6. limited role for HAI-2 in the inhibition of matriptase and prostasin is the result of its primarily intracellular localization in basal and spinous layer keratinocytes, which probably prevents the Kunitz inhibitor from interacting with active prostasin or matriptase

  7. Abrogation of matriptase expression by silencing with RNAi or inhibition of matriptase proteolytic activity with a synthetic inhibitor impairs the conversion of inactive pro-HGF to active HGF and subsequent c-Met-mediated signaling.

  8. Data, including data from studies using cadaver tissue, suggest that matriptase and matriptase mRNA are expressed in several regions of the brain with an enrichment in neurons; higher levels of matriptase RNA are expressed in young individuals as compared to older individuals; matriptase cleaves amyloid beta precursor protein at a specific arginine residue (Arg-102).

  9. Activation of proHGF by St14 induces mouse embryonic stem cell differentiation.

  10. The authors report that ST14/Prss14 is an emerging therapeutic target for breast cancer where HER2 is not applicable.

  11. These results identify EpCAM as a substrate of matriptase and link HAI-2, matriptase, EpCAM, and claudin-7 in a functionally important pathway that causes disease when it is dysregulated.

  12. Matriptase is present in macrophages from patients with mutated alpha-1 antitrypsin at high levels and contributes to their proteolytic activity on extracellular matrix. MMP-14 is a novel substrate for matriptase, which regulates the levels of MMP-14 on the cell surface. High levels of matriptase may contribute to increased ECM degradation by Z-M, both directly and through MMP-14 activation.

  13. Ultraviolet irradiation/reactive oxygen species induced matriptase proteolysis may have short term protective effects and contribute to the recovery from acute epidermal damage and/or pathology of skin with chronic sun damage.

  14. The present study demonstrated that ovarian cancer cell metastasis and invasion were more dependent on upregulation of matriptase levels than downregulation of HAI1. Matriptase may be a potential adjuvant therapeutic target for inhibiting ovarian cancer invasion and metastasis.

  15. Given that matriptase-1 participates in terminal KC differentiation, its absence in psoriatic skin lesions indicates that this contributes to the barrier disturbances in this disease.

  16. Novel findings reveal a new paradigm in matriptase activation involving PDGF-D-specific signal transduction leading to extracellular acidosis.

  17. Maritriptase is required for pro-HGF/c-Met signaling and cell proliferation in breast cancer cells.

  18. Matriptase inhibition by HAI-2 requires the translocation of HAI-2 to the cell surface, a process which is observed in some breast cancer cells but not in mammary epithelial cells.

  19. prostate cancer cell invasion is stimulated by a rapid but sustained increase in Src activity, mediated non-genomically by cytoplasmic AR, leading to rapid activation and shedding of the laminin protease Matriptase

  20. Report potent/specific inhibition of matriptase by the cyclic microprotein MCoTI-II.

Mouse (Murine) Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Interaktionspartner

  1. The catalytic, stem, and transmembrane portions of matriptase-2 are required for suppressing the expression of the iron-regulatory hormone hepcidin.

  2. These results identify EpCAM as a substrate of matriptase and link HAI-2, matriptase, EpCAM, and claudin-7 in a functionally important pathway that causes disease when it is dysregulated.

  3. The proliferation impairment in matriptase-deficient breast cancer cells is caused by their inability to initiate activation of the c-Met signalling pathway in response to fibroblast-secreted pro-HGF.

  4. Matriptase is a critical promoter of late stages of squamous cell carcinoma progression and induces pro-tumorigenic chemokine and cytokine release, and inflammatory cell accumulation in established tumors.

  5. Data show that proteinase-activated receptor (PAR)-2-dependent inflammatory signaling as an essential component of matriptase-mediated and potentiation of ras-mediated oncogenesis.

  6. HAI-1 regulates the activity of activated matriptase, whereas HAI-2 has an essential role in regulating prostasin-dependent matriptase zymogen activation.

  7. Our results reveal unexpected complementary roles of matriptase-prostasin- and PAR-2-dependent proteolytic signaling in the establishment of placental epithelial barrier function and overall embryonic survival.

  8. These findings suggest that TGF-beta induces epithin/PRSS14 shedding by mediating translocation of epithin/PRSS14 sheddase, TACE, to the membrane.

  9. Matriptase deletion initiates a Sjogren's syndrome-like disease in mice.

  10. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.

  11. ST14 expression is downregulated in colitis.

  12. St14 is a critical tumor-suppressor gene in the mouse gastrointestinal tract and adds matriptase to the expanding list of pericellular proteases with tumor-suppressive functions

  13. Overexpression of matriptase in 4T1 mouse breast carcinoma cells resulted in visible changes in morphology, actin staining and cell to cell contacts

  14. matriptase as an initiator of c-Met-Akt-mTor-dependent signaling axis in tumors and mTor activation as an essential component of matriptase/c-Met-induced carcinogenesis

  15. Endogenous expression of matriptase in neural progenitor cells promotes cell migration and neuron differentiation.

  16. Soluble form of the protein secreted from cancer cells contains active angiogenic potential

  17. These results suggest that epithin is a key mediator of TGF-beta-induced epithelial-mesenchymal transition in tumor progression.

  18. Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation

  19. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. (Matriptase/MTSP1)

  20. matriptase is downregulated through suppression of activation of receptor-bound pro-urokinase, and leads to inhibition of tumor invasion

Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Antigen-Profil

Protein Überblick

The protein encoded by this gene is an epithelial-derived, integral membrane serine protease. This protease forms a complex with the Kunitz-type serine protease inhibitor, HAI-1, and is found to be activated by sphingosine 1-phosphate. This protease has been shown to cleave and activate hepatocyte growth factor/scattering factor, and urokinase plasminogen activator, which suggest the function of this protease as an epithelial membrane activator for other proteases and latent growth factors. The expression of this protease has been associated with breast, colon, prostate, and ovarian tumors, which implicates its role in cancer invasion, and metastasis.

Genbezeichner und Symbole assoziert mit ST14

  • suppression of tumorigenicity 14 (ST14) Antikörper
  • suppression of tumorigenicity 14 L homeolog (st14.L) Antikörper
  • suppression of tumorigenicity 14 (colon carcinoma) (St14) Antikörper
  • suppression of tumorigenicity 14 (St14) Antikörper
  • Epithin Antikörper
  • hai Antikörper
  • matriptase Antikörper
  • mCAP3 Antikörper
  • mt-sp1 Antikörper
  • mtsp1 Antikörper
  • Prss14 Antikörper
  • snc19 Antikörper
  • st14 Antikörper
  • st14a Antikörper
  • tadg15 Antikörper
  • tmprss1 Antikörper
  • Tmprss14 Antikörper
  • XMT-SP1 Antikörper

Bezeichner auf Proteinebene für ST14

membrane-type serine protease 1 , prostamin , serine protease 14 , serine protease TADG-15 , suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin) , suppressor of tumorigenicity 14 protein , tumor associated differentially expressed gene 15 protein , tumor-associated differentially-expressed gene 15 protein , matriptase a , suppression of tumorigenicity 14 (colon carcinoma) a , suppressor of tumorigenicity 14 protein homolog , suppressor of tumorigenicity protein 14 , matriptase/MT-SP1 , protease, serine, 14 (epithin) , matriptase , membrane-type serine protease

GENE ID SPEZIES
100101609 Oryctolagus cuniculus
6768 Homo sapiens
394363 Xenopus laevis
767617 Bos taurus
19143 Mus musculus
114093 Rattus norvegicus
Ausgewählte Anbieter für anti-Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Antikörper
Haben Sie etwas anderes gesucht?